Kinase Inhibitor is Highly Active in MET-amplified Gastric Cancer
Country of origin: USA
Click for Full Details: www.practiceupdate.comAn investigational kinase inhibitor that blocks the MET signaling pathway is highly active and well tolerated in patients with gastric and related cancers that have amplification of the MET gene, according to a trial reported at the annual Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology.
Nearly two-thirds of such patients in the open-label phase 1 trial had a response to AMG 337, an oral, potent, and highly selective inhibitor of c-Met, reported lead investigator Dr. Eunice L. Kwak, a medical oncologist at the Massachusetts General Hospital, Boston.
“Dramatic responses to AMG 337 were observed in a subset of patients with MET-amplified esophagogastric cancers. This demonstrates that MET amplification is an oncogenic driver in some of these cancers,” she contended.
Click for Full Details: www.practiceupdate.com
The Linus Pauling Institute February 2018
My PearlPoint Cancer Side Effects January 2018
myCME, continuing medical education January 2018
Clinical Trial Seek app January 2018
Endocrinology Advisor January 2018
Renal & Urology News (RUN) January 2018
Neurology Advisor app January 2018
The Drugs & Bugs app January 2018
inPractice® Oncology January 2018
Reducing the Inappropriate Use of Antibiotics December 2017